OncoZenge AB (publ) (ONCOZ.ST) Research

OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).

Market snapshot

Symbol
ONCOZ.ST
Price
$7.55
Day change
-0.26%
Market cap
$106.1M
P/E ratio
-4.34x
52-week range
4.515-10.28
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • AcouSort AB (publ) (ACOU.ST)
  • Alligator Bioscience AB (publ) (ATORX.ST)
  • ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
  • Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
  • Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)
  • Ortivus AB (publ) (ORTI-B.ST)
  • ScandiDos AB (publ) (SDOS.ST)
  • Simris Alg AB (publ) (SIMRIS-B.ST)

Open OncoZenge AB (publ) (ONCOZ.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.